Volume 23, Supplement—December 2017
SUPPLEMENT ISSUE
Global Health Security Supplement
Overview
Ebola Response Impact on Public Health Programs, West Africa, 2014–2017
Table 1
IDSR priority disease | Q1 2016 | Q2 2016 | Q3 2016 | Q4 2016 | Q1 2017 |
---|---|---|---|---|---|
Acute flaccid paralysis | Sent to WHO/regional laboratory outside Liberia for testing | ||||
Acute watery diarrhea (cholera) | † | † | ‡ | § | § |
Acute bloody diarrhea (shigella) | † | † | ‡ | § | § |
Human rabies | Sent to WHO/regional Laboratory outside Liberia for testing | ||||
Lassa fever | † | † | ‡ | § | § |
Measles | ‡ | § | § | § | § |
Meningitis | † | † | † | ‡ | § |
Neonatal tetanus | Not applicable; diagnoses based on clinical symptoms | ||||
Viral hemorrhagic fever (including Ebola virus disease) | § | § | § | § | § |
Yellow fever | ‡ | § | § | § | § |
*IDSR, Integrated Disease Surveillance and Response framework; Q, quarter, WHO, World Health Organization.
†Capacity was not available during the specified quarter.
‡Capacity was partially established.
§Established laboratory capacity.
Page created: November 20, 2017
Page updated: November 20, 2017
Page reviewed: November 20, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.